Myriad Genetics (NASDAQ:MYGN) Downgraded by StockNews.com to “Hold”
StockNews.com cut shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research note released on Thursday. A number of other equities research analysts also recently issued reports on the company. Morgan Stanley lowered their price objective on Myriad Genetics from $32.00 to $21.00 and set an […]
